Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases

Bibliography

• Federoff HJ. Novel targets for CNS gene therapy. Gene Ther 1999;6(12):1907-8
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today 2002;7(1):5-7
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3(2):219-32
   PubMedGoogle Scholar
• Azzouz M, Ralph S, Wong LF, et al. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport 2004;15(6):985-90
   PubMed Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood–brain barrier. Adv Drug Deliv Rev 2001;46(1-3):247-79
   PubMed Web of Science ®Google Scholar
• Abdellatif AA, Pelt JL, Benton RL, et al. Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systems. J Neurosci Res 2006;84(3):553-67
   PubMed Web of Science ®Google Scholar
• Berry M, Barrett L, Seymour L, et al. Gene therapy for central nervous system repair. Curr Opin Mol Ther 2001;3(4):338-49
   PubMed Web of Science ®Google Scholar
• Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Ther 2000;7(2):93-109
   PubMed Web of Science ®Google Scholar
• Federoff HJ. CNS diseases amenable to gene therapy. Ernst Schering Res Found Workshop 2003;(43):117-58
   PubMedGoogle Scholar
• Friedmann T. Gene therapy for disorders of the CNS. Gene Ther 1994;1(Suppl 1):S47-8
   PubMedGoogle Scholar
• Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-5
   PubMed Web of Science ®Google Scholar
• Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17
   PubMed Web of Science ®Google Scholar
• Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx 2005;2(4):554-71
   PubMedGoogle Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
   PubMed Web of Science ®Google Scholar
• Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6(5):341-2
   PubMed Web of Science ®Google Scholar
• Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355(15):1525-38
   PubMed Web of Science ®Google Scholar
• Lim G. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21(21):8370-7
   PubMed Web of Science ®Google Scholar
• Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-40
   PubMed Web of Science ®Google Scholar
• Tobinick E, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflamm 2008;5(1):2
   PubMed Web of Science ®Google Scholar
• Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurology 2002;1(1):51-7
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11(5):551-5
   PubMed Web of Science ®Google Scholar
• Opar A. Mixed results for disease-modification strategies for Alzheimer's disease. Nat Rev Drug Discov 2008;7(9):717-8
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Horn S. Parkinson's disease – Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008;14:S40-8
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Horn S. Parkinson's disease – Part 2: Treatment of motor symptoms. Am J Manag Care 2008;14:S49-58
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290(5492):767-73
   PubMed Web of Science ®Google Scholar
• Manfredsson FP, Lewin AS, Mandel RJ. RNA knockdown as a potential therapeutic strategy in Parkinson's disease. Gene Ther 2005;13(6):517-24
   Web of Science ®Google Scholar
• Walker FO. Huntington's disease. Lancet 2007;369:218-28
   PubMed Web of Science ®Google Scholar
• Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008;412:191-209
   PubMed Web of Science ®Google Scholar
• Adam OR, Jankovic J. Symptomatic treatment of Huntington Disease. Neurotherapeutics 2008;5:181-97
   PubMed Web of Science ®Google Scholar
• Machida Y, Okada T, Kurosawa M, et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 2006;343(1):190-7
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3–14
   PubMedGoogle Scholar
• Ehrlich P. Das Sauerstoff-Bedurfniss des Organismus, eine farbanalytische Studie. Hirschwald, Berlin, 1885
   Google Scholar
• Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57(2):173-85
   PubMed Web of Science ®Google Scholar
• Reese TS, Karnovsky MJ. Fine structural localization of a blood–brain barrier to exogenous peroxidase. J Cell Biol 1967;34(1):207-17
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006;7:41-53
   PubMed Web of Science ®Google Scholar
• Zlokovic B. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57(2):178-201
   Google Scholar
• Ghersi-Egea JF, Minn A, Siest G. A new aspect of the protective functions of the blood–brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci 1988;42(24):2515-23
   PubMed Web of Science ®Google Scholar
• Minn A, Ghersi-Egea JF, Perrin R, et al. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Rev 1991;16(1):65-82
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555-8
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Recent developments in peptide drug delivery to the brain. Pharmacol Toxicol 1992;71(1):3-10
   PubMedGoogle Scholar
• Strasser JF, Fung LK, Eller S, et al. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther 1995;275(3):1647-55
   PubMed Web of Science ®Google Scholar
• Storm PB, Moriarity JL, Tyler B, et al. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol 2002;56(3):209-17
   PubMed Web of Science ®Google Scholar
• Ernerich DF, Plone M, Francis J, et al. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res 1996;736(1-2):99-110
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459
   PubMed Web of Science ®Google Scholar
• Hovland DN, Boyd RB, Butt MT, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in Rhesus monkeys. Toxicol Pathol 2007;35(5):676
   PubMed Web of Science ®Google Scholar
• Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15(10):968-75
   PubMed Web of Science ®Google Scholar
• Zünkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood–brain barrier disruption in humans. J Neurosurg 1996;85(6):1056-65
   PubMed Web of Science ®Google Scholar
• Wennberg R. The blood–brain barrier and bilirubin encephalopathy. Cell Mol Neurobiol 2000;20(1):97-109
   PubMed Web of Science ®Google Scholar
• Hanig JP, Morrison JM Jr, Krop S. Ethanol enhancement of blood–brain barrier permeability to catecholamines in chicks. Eur J Pharmacol 1972;18(1):79-82
   PubMed Web of Science ®Google Scholar
• Broadwell RD, Salcman M, Kaplan RS. Morphologic effect of dimethyl sulfoxide on the blood–brain barrier. Science 1982;217(4555):164-6
   PubMed Web of Science ®Google Scholar
• Dudeja PK, Anderson KM, Harris JS, et al. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995;319(1):309-15
   PubMed Web of Science ®Google Scholar
• Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003;92(6):1250-61
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-ß attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7
   PubMed Web of Science ®Google Scholar
• Raymond SB, Treat LH, Dewey JD, et al. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS ONE 2008;3(5):e2175
   PubMed Web of Science ®Google Scholar
• Ferrer I, Rovira MB, Guerra MLS, et al. Neuropathology and pathogenesis of encephalitis following amyloid ß Immunization in Alzheimer's disease. Brain Pathol 2004;14(1):11-20
   PubMed Web of Science ®Google Scholar
• NCBI. PubChem Compound. cited; Available from: http://pubchem.ncbi.nlm.nih.gov/
   Google Scholar
• Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. Eleventh editon. In: Brunton LL, editor, Goodman and Gillman's Pharmacologic basis of therapeutics. New York: McGraw-Hill; 2006. p. 527-45
   Google Scholar
• Martel CL, Mackic JB, Adams JD, et al. Transport of Dopamine at the blood–brain barrier of the guinea pig: inhibition by psychotropic drugs and nicotine. Pharm Res 1996;13(2):290-5
   PubMed Web of Science ®Google Scholar
• Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000;879(1-2):115-21
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv Drug Deliv Rev 1999;36(2-3):277-90
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Molecular Trojan horses for blood–brain barrier drug delivery. Curr Opin Pharm 2006;6:494-500
   PubMed Web of Science ®Google Scholar
• Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 2002;57(5):365-80
   PubMed Web of Science ®Google Scholar
• Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharm Ther 2000;68:231-7
   PubMed Web of Science ®Google Scholar
• Bodor N, Prokai L, Wu WM, et al. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992;257(5077):1698-700
   PubMed Web of Science ®Google Scholar
• Wu J, Yoon SH, Wu WM, Bodor N. Synthesis and biological evaluations of brain-targeted chemical delivery systems of [Nva2]-TRH. J Pharm Pharmacol 2002;54(7):945-50
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005;94:1187-95
   PubMed Web of Science ®Google Scholar
• Tirucherai GS, Yang C, Mitra AK. Prodrugs in nasal drug delivery. Expert Opin Biol Ther 2001;1(1):49-66
   PubMed Web of Science ®Google Scholar
• Bagger MA, Bechgaard E. The potential of nasal application for delivery to the central brain – a microdialysis study of fluorescein in rats. Eur J Pharm Sci 2004;21(2-3):235-42
   PubMed Web of Science ®Google Scholar
• De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102(10):3811-6
   PubMed Web of Science ®Google Scholar
• Laursen T, Grandjean B, Jorgensen JO, Christiansen JS. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration. Eur J Endocrinol 1996;135(3):309-15
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Thorne RG, et al. Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187(1-2):91-7
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Thorne RG, Frey WH 2nd. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001;308(2):91-4
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2005;2(2):165-75
   PubMedGoogle Scholar
• Lawrence D. Intranasal delivery could be used to administer drugs directly to the brain. Lancet 2002;359(9318):1674
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, et al. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech 2006;7(1):E8
   PubMedGoogle Scholar
• Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56(1):3-17
   PubMed Web of Science ®Google Scholar
• Invitti C, Fatti L, Camboni MG, et al. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. J Endocrinol Invest 1996;19(8):548-55
   PubMed Web of Science ®Google Scholar
• Fehm HL, Perras B, Smolnik R, et al. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharmacol 2000;405(1-3):43-54
   PubMed Web of Science ®Google Scholar
• Haruta S, Hanafusa T, Fukase H, et al. An effective absorption behavior of insulin for diabetic treatment following intranasal delivery using porous spherical calcium carbonate in monkeys and healthy human volunteers. Diabetes Technol Ther 2003;5(1):1-9
   PubMedGoogle Scholar
• Gozes I, Giladi E, Pinhasov A, et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000;293(3):1091-8
   PubMed Web of Science ®Google Scholar
• Zhao HM, Liu XF, Mao XW, Chen CF. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 2004;19(4):257-61
   PubMedGoogle Scholar
• Shi J, Perry G, Berridge MS, et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 2002;43(8):1044-51
   PubMed Web of Science ®Google Scholar
• Merkus FWHM, van den Berg MP. Can nasal drug delivery bypass the blood–brain barrier? Drugs R D 2007;8(3):133-44
   PubMedGoogle Scholar
• Vyas TK, Tiwari SB, Amiji MM. Formulation and physiological factors influencing CNS delivery upon intranasal administration. Crit Rev Ther Drug Carrier Syst 2006;23(4):319-47
   PubMed Web of Science ®Google Scholar
• Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007;96(10):2547-65
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3:219-32
   PubMedGoogle Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci 1996;93:14164-9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002;6(1):67-72
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002;1(2):131-9
   PubMed Web of Science ®Google Scholar
• McClements DJ, Decker EA, Weiss J. Emulsion-based delivery systems for lipophilic bioactive components. J Food Sci 2007;72:R109-24
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm 2008;347:93-101
   PubMed Web of Science ®Google Scholar
• Bernoud N, Fenart L, Benistant C, et al. Astrocytes are mainly responsible for the polyunsaturated fatty acid enrichment in blood-brain barrier endothelial cells in vitro. J Lipid Res 1998;39:1816-24
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10(4):327-35
   PubMed Web of Science ®Google Scholar
• Lockman PR, Oyewumi MO, Koziara JM, et al. Brain uptake of thiamine-coated nanoparticles. J Control Release 2003;93(3):271-82
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995;674(1):171-4
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004;25(15):3065-71
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14
   PubMedGoogle Scholar
• Hanson LR, Frey WH 2nd. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007;2(1):81-6
   PubMed Web of Science ®Google Scholar
• Thorne RG, Frey WH 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40(12):907-46
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
   PubMed Web of Science ®Google Scholar
• Steinman MDL. Multiple Sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996;85(3):299-302
   PubMed Web of Science ®Google Scholar
• Preux PM, Druet-Cabanac M, Couratier P, et al. Estimation of the amyotrophic lateral sclerosis incidence by capture–recapture method in the Limousin region of France. J Clin Epidemiol 2000;53(10):1025-9
   PubMed Web of Science ®Google Scholar
• Sun M, Kong L, Wang X, et al. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005;1052(2):119-29
   PubMed Web of Science ®Google Scholar
• Aebischer P, Ridet JL. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci 2001;24(9):533-40
   PubMed Web of Science ®Google Scholar
• Kordower JH, Isacson O, Emerich DF. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp Neurol 1999;159:4-20
   PubMed Web of Science ®Google Scholar
• Shibata S, Ochi A, Mori K. Liposomes as carriers of cisplatin into the central nervous system–experiments with 9L gliomas in rats. Neurol Med Chir (Tokyo) 1990;30(4):242-5
   PubMedGoogle Scholar
• Yamada K, Moriguchi A, Morishita R, et al. Efficient oligonucleotide delivery using the HVJ-liposome method in the central nervous system. Am J Physiol Regul Integr Comp Physiol 1996;271(5):R1212-20
   PubMed Web of Science ®Google Scholar
• Teresa Girão da Cruz M, Cardoso ALC, de Almeida LP, et al. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 2005;12(16):1242-52
   PubMed Web of Science ®Google Scholar
• Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neurooncol 2007;9(4):393-403
   Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004;99(2):259-69
   PubMed Web of Science ®Google Scholar
• Reddy L, Sharma R, Chuttani K, et al. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS Journal 2004;6(3):55-64
   Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59(3):299-307
   PubMed Web of Science ®Google Scholar
• Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29(33):4429-38
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood–brain barrier. Int J Pharm 2006;327:160-9
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Khalansky AS, Yamamoto H, et al. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14 C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 2006;14(2):97-105
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007;122(1):1-9
   PubMed Web of Science ®Google Scholar
• Costantino L, Gandolfi F, Tosi G, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier. J Control Release 2005;108(1):84-96
   PubMed Web of Science ®Google Scholar
• Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007;21(4):1117-25
   PubMed Web of Science ®Google Scholar